On February 28, the 2021 performance express of science and innovation board company was fully “checked in”, and a hard core “report card” with stable and rising annual performance appeared.
90% of the company’s revenue increased, and a number of hard science and technology leaders led the development of the whole industrial chain; The net profit of 55 companies doubled, and the “epidemic” of hard core war and green development activated the driving force of scientific innovation; Six unprofitable companies are expected to pick “U” at the time of listing, highlighting the inclusiveness of the science and Innovation Board… In 2021, the overall performance of the science and Innovation Board continued to grow at a high rate, reflecting the potential and vitality of China’s scientific and technological innovation enterprises from one side.
90% of the company’s revenue growth
leading sub track
From the data, in 2021, the overall performance of the science and Innovation Board continued its high growth trend, realizing a bumper harvest of operating revenue and net profit.
According to preliminary statistics, in 2021, listed companies on the science and Innovation Board achieved a total operating revenue of 812693 billion yuan, a year-on-year increase of 36%; The total net profit attributable to the parent company was 92.909 billion yuan, a year-on-year increase of 72%. Among them, nearly 90% of the companies achieved a year-on-year increase in operating revenue, 111 companies had a year-on-year increase of more than 50%, and 40% of the companies had an operating revenue of more than 1 billion yuan. Nearly 70% of the companies realized a year-on-year increase in the net profit attributable to the parent company, and the net profit of 55 companies doubled year-on-year, Beijing Hotgen Biotech Co.Ltd(688068) “taking the lead”, with an increase of more than 18 times.
The company is highly concentrated in high-tech industries and strategic emerging industries. It plays an increasingly prominent role in serving the national strategy, helping enterprises transform and upgrade and promoting high-quality economic development. In many hard science and technology fields, a number of key technology researchers such as Semiconductor Manufacturing International Corporation(688981) , shengmei Shanghai and Shanghai Anlogic Infotech Co.Ltd(688107) have made use of the capital market to realize the deep integration of innovation chain, industrial chain, talent chain, policy chain and capital chain, and shine brightly in innovation driven development.
On February 24, Shanghai Bright Power Semiconductor Co.Ltd(688368) launched the “first shot” of the 2021 annual report of Kechuang board integrated circuit industry chain company.
Thanks to the strong downstream demand of the industry, the company continued to strengthen supply chain management, optimize product structure and adjust product prices. In 2021, the company achieved an operating revenue of 2.302 billion yuan, a year-on-year increase of 109%; The net profit attributable to the parent company was 677 million yuan, a year-on-year increase of 884%, and the gross profit margin increased significantly from 25% to 48%. “Core” company has many new drivers. In 2021, Shanghai Bright Power Semiconductor Co.Ltd(688368) while the LED lighting driving business grew steadily, it also actively expanded the “second curve” to achieve a comprehensive breakthrough in the business of built-in and external AC / DC power chips.
In 2021, Semiconductor Manufacturing International Corporation(688981) production capacity expanded significantly, and a number of financial indicators reached record highs. The performance express shows that in the face of the global core shortage tide and strong demand, Semiconductor Manufacturing International Corporation(688981) annual operating revenue was 35.631 billion yuan, an increase of 30% year-on-year; The net profit attributable to the parent company was 10.733 billion yuan, a year-on-year increase of 148% Semiconductor Manufacturing International Corporation(688981) has become the fastest growing company among the top four pure wafer foundry in the world.
“green development” leads the trend of scientific innovation
specialized new “little giants” get together
The goal of “double carbon” points out the direction. The science and innovation board company accelerates the cultivation of “green engine”, and a number of specialized “small giants” stand out, injecting a force of sustainable development into the 2021 annual report.
In 2021, the new energy industry of the science and Innovation Board achieved a total operating revenue of 152098 billion yuan, a year-on-year increase of 38%; The total net profit attributable to the parent company was 12.789 billion yuan, a year-on-year increase of 97%; 90% of the company achieved double growth in revenue and net profit. Driven by the continuous improvement of the overall prosperity of the industry and the advantages of advanced technology, the net profits of four upstream enterprises in the photovoltaic industry chain, including Xinjiang Daqo New Energy Co.Ltd(688303) , Kbc Corporation Ltd(688598) and Kbc Corporation Ltd(688598) doubled, of which Xinjiang Daqo New Energy Co.Ltd(688303) increased by 449%. Riding the east wind of new energy vehicle industry, power battery enterprises are busy expanding production Hunan Changyuan Lico Co.Ltd(688779) , Ningbo Ronbay New Energy Technology Co.Ltd(688005) net profit attributable to parent company increased by 538% and 328% respectively year on year.
Kbc Corporation Ltd(688598) ‘s advanced composite products are mainly used in the thermal field system of photovoltaic monocrystalline silicon drawing furnace, and the downstream main customers are enterprises in the field of photovoltaic crystalline silicon manufacturing. Benefiting from the steady growth of downstream photovoltaic industry scale and strong market demand, the company continued to expand production capacity, and its operating revenue and net profit attributable to parent increased by 214% and 197% respectively.
In the more than two years since the opening of the sci-tech innovation board, 115 “little giant” enterprises specializing in special innovation have gathered, accounting for nearly 30% of the total number of Sci-tech Innovation Board companies.
In 2021, the total operating revenue and net profit attributable to the parent of these “little giants” increased by 39% and 42% respectively year-on-year. More than 60% of the company’s revenue and net profit increased, and many companies became “invisible champions” of subdivided tracks.
At the semiconductor equipment track, the first batch of national specialized and new “little giant” enterprises Kingsemi Co.Ltd(688037) last year, the newly signed orders increased significantly year-on-year, realizing an operating revenue of 829 million yuan, a year-on-year increase of 152%; The net profit deducted from non parent company was 636813 million yuan, with a year-on-year increase of 395%.
diversity and inclusiveness boost innovation and development
6 companies are expected to pick “U”
On the stage of sci-tech innovation board, a group of companies with “U” small tail have been attracting the attention of the market. In 2021, 31 unprofitable enterprises at the time of listing operated steadily and well, and the effect of inclusive system gradually appeared.
Guizhou Zhenhua E-Chem Inc(688707) , Tianyue advanced and other 7 companies turned their net profits back to the parent company, and 6 companies are expected to realize positive net profits before and after deduction for the first time after listing. The “small tail” after the abbreviation of securities will also be removed after the official disclosure of the 2021 annual report to realize “U”.
In 2021, Cansino Biologics Inc(688185) achieved an operating revenue of 4.3 billion yuan, a year-on-year increase of 17175%; The net profit attributable to the parent company was 1.91 billion yuan, turning losses into profits year-on-year. In addition, there are Shanghai Allist Pharmaceuticals Co.Ltd(688578) , Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) , Sinocelltech Group Limited(688520) and other innovative drug enterprises listed on the fifth set of standards of the science and innovation board, which first launched domestic innovative drugs to the market in 2021, and the drug sales revenue began to take shape.
The development process of Sci-tech Innovation Board enterprises has certain uncertainty. On the one hand, affected by the impact of supply side, repeated global epidemic, industrial adjustment and other factors, the demand of some industries has weakened, the price of raw materials has increased, and the operation of enterprises is under pressure; On the other hand, the operation scale of sci-tech innovation board company is small, the products and business models of some companies are not fully mature, the commercialization of innovation and R & D is uncertain, the customers are relatively concentrated, the bargaining power of the industrial chain is not high, and the inherent business risks may be amplified due to the change of the external environment.
For example, the fifth set of listing criteria of the science and innovation board takes “market value + products + phased achievements” as the listing condition, which opens a window for unprofitable innovative pharmaceutical enterprises. However, these enterprises still face risks such as R & D, commercialization transformation, product listing process less than expected, and intensified market competition.
In the view of capital market research experts, for the performance fluctuations in the normal operation of science and Innovation Board enterprises in the growth stage, we need to give more patience and peace of mind to accompany and help enterprises grow together.
